Form 4: Edwards Lifesciences Executive Sells Shares Under Pre-Arranged Trading Plan

Donald E. Bobo Jr., CVP of Strategy and Corporate Development at Edwards Lifesciences Corp, sold 2,570 shares of common stock for approximately $77.40 per share under a Rule 10b5-1 trading plan.

Summary

• Donald E. Bobo Jr., the CVP of Strategy and Corporate Development at Edwards Lifesciences Corp (EW), reported a transaction involving the company's common stock.
• On June 2, 2025, Mr. Bobo sold 2,570 shares of Edwards Lifesciences common stock.
• The shares were sold at a weighted average price of $77.3974 per share, with individual trade prices ranging from $77.36 to $77.68.
• This transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan, which Mr. Bobo adopted on February 27, 2025.
• Following this sale, Mr. Bobo's direct beneficial ownership of common stock is 50,356.3707 shares.
• His indirect beneficial ownership includes 38,817.6991 shares held in a 401(k) plan and 135,152 shares held by a trust.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale under a Rule 10b5-1 plan, which is generally considered neutral as it's pre-scheduled and not indicative of immediate sentiment regarding the company's prospects.

Future Outlook

NA

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even under a pre-arranged plan, slightly reduces insider alignment, though the impact is generally considered neutral given the routine nature of 10b5-1 transactions.

Key Dates

Keywords

Edwards Lifesciences, EW, Form 4, insider trading, stock sale, beneficial ownership, Rule 10b5-1, corporate officer, common stock